Payment overview · 2025
General Payments
$3,270.76
28 reported records · 17 companies
Healthcare provider profile · identity verified
Renee Higa-Tanner
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MURRIETA, CA · NPI 1942943170
Verified facts
What the public records show
CMS Open Payments records show Renee Higa-Tanner received $3,270.76 in general payments during 2025 across 28 reported records.
Axsome Therapeutics, Inc. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $738.47 | 22.6% | 6 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $271.64 | 8.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $249.97 | 7.6% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $248.22 | 7.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $246.90 | 7.5% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $150.00 | 4.6% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $149.98 | 4.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.86 | 4.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $131.43 | 4.0% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $125.00 | 3.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.00 | 3.8% | 1 | 2025 |
| Amarin Pharma, Inc. | Unresolved — no canonical attribution shown | $124.99 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.91 | 3.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $121.82 | 3.7% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $114.34 | 3.5% | 3 | 2025 |
| Hydrofera LLC | Unresolved — no canonical attribution shown | $108.23 | 3.3% | 1 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $100.00 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,270.76 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $372.81 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $365.66 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $248.22 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $246.90 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $149.98 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $142.86 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $131.43 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Vascepa Normalized: vascepa |
Drug | Amarin Pharma, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.97 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.97 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.91 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $121.82 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $114.34 | 3 | 2025 |
Source payment records
|
|||||
| HYDROFERA BLUE Normalized: hydrofera blue |
Device | Hydrofera LLC | $108.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 171 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 134 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 115 | 40 |
| Lisinopril | Lisinopril | 113 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 108 | 40 |
| Gabapentin | Gabapentin | 95 | 25 |
| Metformin Hcl | Metformin Hcl | 89 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 23 |
| Alendronate Sodium | Alendronate Sodium | 69 | 24 |
| Omeprazole | Omeprazole | 66 | 27 |
| Alprazolam | Alprazolam | 62 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 17 |
| Losartan Potassium | Losartan Potassium | 57 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 46 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 14 |
| Allopurinol | Allopurinol | 44 | 13 |
| Clonazepam | Clonazepam | 44 | 12 |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 44 | suppressed |
| Ozempic | Semaglutide | 42 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | 11 |
| Furosemide | Furosemide | 39 | 15 |
| Rexulti | Brexpiprazole | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 19 |
| Atenolol | Atenolol | 34 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Methadone Hcl | Methadone Hcl | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | 12 |
| Simvastatin | Simvastatin | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 13 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,270.76 · 28 records | Axsome Therapeutics, Inc. | AIRSUPRA, AVYCAZ, Arikayce, Auvelity, CRENESSITY, DUPIXENT, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), HYDROFERA BLUE, KRYSTEXXA, LYBALVI, MOUNJARO, QULIPTA, Senza, Symbravo, TZIELD, UBRELVY, VOQUEZNA, Vascepa | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error